ClinicalTrials.gg
RecruitingNCT06974110Updated Jul 23, 2026

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of MOMA-341 and Irinotecan in Advanced Solid Tumor, Metastatic Solid Tumor and Endometrial Cancer, sponsored by MOMA Therapeutics. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by MOMA Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
421st of 1,864
132 · median 43
Started
2025
with 84 others
Phase 1
710 of 2,055
129 open now
Primary completion
2027-11
later than 311 of 541 live
Registered
1,937th of 2,055
by date

Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 421st largest by planned enrollment of the 1,864 interventional ones that give a count, is one of 85 that started in 2025, is one of 710 in phase 1, reaches primary completion later than 311 of the 541 other live ones, and was the 1,937th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,055 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.

Read the detailed description

MOMA-341 is a novel therapeutic agent designed to target microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) cancers by inhibiting Werner helicase. MOMA-341 is being developed as a single agent and in combination with either chemotherapy or immunotherapy in patients with certain advanced or metastatic solid tumors.

This phase 1, first-in-human, open-label study of MOMA-341 is primarily intended to evaluate the safety and tolerability of MOMA-341 when administered orally as a single agent (Treatment Arm 1), in combination with irinotecan (Treatment Arm 2), or in combination with immunotherapy (Treatment Arm 3). Each treatment arm of the study includes a dose-escalation phase, which means successive cohorts of patients will receive increasing oral doses of MOMA-341 as a single agent or in combination with irinotecan or immunotherapy to determine the presumptive optimal biologic dose(s) (OBD) in this population. The study also includes a dose-optimization phase that will enroll additional patients to support the confirmation of the OBD.

The data from this study conducted in patients with MSI-H or dMMR advanced or metastatic solid tumors, including safety, tolerability, PK/PDx findings, and antitumor activity, will form the basis for subsequent clinical development of MOMA-341 as a single-agent and in combination with irinotecan or immunotherapy.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Endometrial Cancer
  • MSI-H Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • dMMR Cancer

Keywords

  • Phase 1
  • MOMA-341
  • Werner helicase
  • WRN
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Gastric Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • MSI-H Cancer
  • dMMR Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Participants have unresectable advanced or solid tumors with MSI-H or dMMR alterations and confirmed disease. Participants must have previously received and progressed on an anti-PD-(L)1-based regimen, unless ineligible or in a region without access to anti-PD-(L)1 therapies
  3. Have at least 1 lesion at baseline (measurable or non-measurable) suitable for repeat imaging evaluation by and/or PCWG-3
  4. PS ≤ 2
  5. Fully recovered from effects of prior therapy, radiotherapy, and/or surgery **hormonal therapy allowed. Palliative radiotherapy allowed
  6. Adequate organ function per local labs
  7. Comply with requirements
  8. Written must be obtained according to local guidelines

Exclusion criteria

Exclusion Criteria:

  1. Known Werner Syndrome
  2. Active prior or concurrent advanced-stage (some exceptions allowed including early-stage cancers)
  3. cardiovascular disease
  4. Known associated with progressive neurological symptoms (stable doses of allowed)
  5. Known active uncontrolled infection
  6. Known allergy, , and/or intolerance to MOMA-341
  7. Impaired GI function that may impact absorption
  8. Patient is pregnant or breastfeeding
  9. Known to be positive, unless all of the following criteria are met:

    1. Undetectable viral load or ≥300 cells/μL
    2. Receiving highly active antiretroviral therapy
    3. No AIDS-related illness within the past 12 months
  10. Active liver disease (some exceptions are allowed)
  11. Prior or ongoing condition, therapy, or laboratory abnormality that, in the investigator's opinion, may affect safety of the patient, confound the results of the study, and/or interfere with the patients participation in the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    MOMA-341 Monotherapy (Treatment Arm 1)

    MOMA-341 administered as a single agent in 21-day cycles

    Drug: MOMA-341

  • Experimental
    MOMA-341 in Combination with Irinotecan (Treatment Arm 2)

    MOMA-341 administered together with irinotecan in 28-day cycles

    Drug: MOMA-341 · Drug: Irinotecan

  • Experimental
    MOMA-341 in Combination with Immunotherapy (Treatment Arm 3)

    MOMA-341 administered together with immunotherapy in 21-day cycles

    Drug: MOMA-341 · Drug: Immunotherapy

Interventions

  • DrugMOMA-341

    MOMA-341 administered orally

  • Irinotecan administered by IV infusion

  • DrugImmunotherapy

    Immunotherapy administered by IV infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), and/or AEs leading to discontinuation

    To assess the safety and tolerability of MOMA-341 given as a single-agent, and in combination with irinotecan, and in combination with immunotherapy

    Time frame: From screening until treatment discontinuation (up to 35 months)

Secondary outcomes

  1. Identify the recommended phase 2 dose (RP2D)

    Determine the RP2D of MOMA-341 as a single-agent, and in combination with irinotecan, and in combination with immunotherapy

    Time frame: From screening until treatment discontinuation (up to 35 months)

  2. PK parameter; area under curve (AUC) of MOMA-341

    Determine the AUC of MOMA-341 as a single-agent, and in combination with irinotecan, and in combination with immunotherapy

    Time frame: Up to 6 weeks with sparse sampling up to 35 months

  3. PK parameter; maximum concentration (Cmax) of MOMA-341

    Determine the Cmax of MOMA-341 as a single-agent, and in combination with irinotecan, and in combination with immunotherapy

    Time frame: Up to 6 weeks with sparse sampling up to 35 months

  4. PK parameter; time to maximum concentration (Tmax) of MOMA-341

    Determine the Tmax of MOMA-341 as a single-agent, and in combination with irinotecan, and in combination with immunotherapy

    Time frame: Up to 6 weeks with sparse sampling up to 35 months

  5. PK parameter; half-life (T1/2) of MOMA-341

    Determine the T1/2 of MOMA-341 as a single-agent, and in combination with irinotecan, and in combination with immunotherapy

    Time frame: Up to 6 weeks with sparse sampling up to 35 months

  6. PK parameter; plasma exposure of irinotecan

    Determine the plasma exposure of irinotecan in combination with MOMA-341

    Time frame: Up to 6 weeks with sparse sampling up to 35 months

  7. Objective response rate (ORR)

    ORR is defined as the percentage of subjects with evidence of a complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and/or Prostate Cancer Working Group-3 (PCWG-3)

    Time frame: Up to 35 months

  8. Duration of response (DOR)

    DOR is defined as time from first documented PR or better to disease progression (as assessed by RECIST v1.1 and/or PCWG-3 by Investigator assessment) or death, whichever is earlier, for participants who have achieved a CR or PR

    Time frame: Up to 35 months

  9. Time to response (TTR)

    TTR is defined as the period of time from the date of first dose of study treatment until the first objective documentation of a CR or PR per RECIST 1.1 and/or PCWG-3)

    Time frame: Up to 35 months

  10. Progression free survival (PFS)

    PFS is defined as the time from first dose of study treatment to progressive disease or death from any cause, whichever is earlier, as assessed by RECIST 1.1 and/or PCWG-3 by investigator assessment

    Time frame: Up to 35 months

  11. Disease control rate (DCR)

    DCR is defined as the proportion of subjects who achieved either CR, PR, or stable disease (SD) at the first scheduled disease assessment according to disease-specific response criteria

    Time frame: Up to 35 months

  12. Overall survival (OS)

    OS is defined as the time from first dose of study treatment to the date of death, irrespective of the cause of death

    Time frame: Up to 35 months

07

Study locations

13 of 15 sites recruiting
  • Investigative Site #132
    Phoenix, Arizona 85054, United States
    Recruiting
  • Investigative Site #101
    San Diego, California 92037, United States
    Recruiting
  • Investigative Site #128
    Tampa, Florida 33612, United States
    Recruiting
  • Investigative Site #120
    Detroit, Michigan 48201, United States
    Recruiting
  • Investigative Site #110
    St Louis, Missouri 63108, United States
    Recruiting
  • Investigative Site #131
    Raleigh, North Carolina 27710, United States
    Recruiting
  • Investigative Site #121
    Portland, Oregon 97239, United States
    Recruiting
  • Investigative Site #127
    Dallas, Texas 75230, United States
    Completed

    Not enrolling at this site.

  • Investigative Site #129
    Houston, Texas 77030, United States
    Recruiting
  • Investigative Site #122
    Sydney, New South Wales 2031, Australia
    Recruiting
  • Investigative Site #123
    Westmead, New South Wales 2145, Australia
    Recruiting
  • Investigative Site #124
    Woolloongabba, Queensland 4102, Australia
    Completed

    Not enrolling at this site.

  • Investigative Site #125
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Investigative Site #126
    Clayton, Victoria 3168, Australia
    Recruiting
  • Investigative Site #119
    Perth, Western Australia 6009, Australia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2027, 28 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 28 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 15, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Nov 2027
CompletionEst.
May 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06974110
Lead sponsor
MOMA Therapeutics
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jul 16, 2025
Primary completion
Nov 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 23, 2026

Study contacts

MOMA Clinical Trials
Contact
clinicaltrials@momatx.com
857-285-3677

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion